Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALA.AX
Strong SellArovella Therapeutics Limited · Healthcare · Australia · $53M · Avg Vol: $27K/d
14
StockRankGet insider-trade alerts
Q
37
V
25
M
29
P/E (TTM)
—
ROE
-40.4%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0.3M | 0.4M | 17.0K | 0.1M | -22.8% | — |
| EPS (AUD) | -0.02 | -0.01 | -0.01 | -0.01 | — | -0.01 |
| Shares | 669.8M | 849.9M | 1.1B | 1.2B | +77.4% | 1.2B |
| Debt | 0.1M | — | — | — | — | — |
| Equity | 7.6M | 3.8M | 11.2M | 20.1M | 38.1% | — |
| Op CF | -6.3M | -6.4M | -6.9M | -6.9M | — | -6.9M |
| Inv CF | -0.6M | 95.4K | -0.2M | -0.4M | — | — |
| Fin CF | 6.2M | 5.4M | 14.6M | 15.5M | — | — |
Loading 1Y...
PRICE (1Y)-6.2%
SMA 50SMA 200
Close
$0.0437
RSI (14)
52.9
52W High
$0.0896
From 52W High
0.5%
SCORE BREAKDOWN
Quality
37
ROIC
-55.7%15.0
ROE
-40.4%22.3
GP/Assets
16.9%39.7
Op. Margin
-1874.7%5.6
FCF/Assets
-20.4%21.6
Piotroski
440.0
Int. Cover
—N/A
D/E Ratio
0.00x97.9
Current Ratio
17.51x94.4
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-8.0x25.0
P/FCF
—N/A
P/B
5.1x27.8
P/S
21.1x16.7
Div Yield
—N/A
Momentum
29
52W High %
49%21.6
RS 6M
-21%41.0
SMA 50/200
0.84x24.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$53M
P/E (Forward)
-6.1x
Gross Margin
100.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALA.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALA.AX | Arovella Therapeutics Limited(you) | $53M | 14 | Strong Sell |
| IMM.AX | Immutep Limited | $53M | 9 | Strong Sell |
| BOT.AX | Botanix Pharmaceuticals Limited | $51M | 9 | Strong Sell |
| PTX.AX | Prescient Therapeutics Limited | $50M | 22 | Sell |
| LTP.AX | LTR Pharma Limited | $61M | 24 | Sell |
| ATX.AX | Amplia Therapeutics Limited | $53M | 30 | Sell |
| ILA.AX | Island Pharmaceuticals Limited | $93M | 19 | Strong Sell |
| ACW.AX | Actinogen Medical Limited | $118M | 18 | Strong Sell |
| RCE.AX | Recce Pharmaceuticals Ltd | $81M | 2 | Strong Sell |
| PAR.AX | Paradigm Biopharmaceuticals Limited | $91M | 4 | Strong Sell |
Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 61.1%